EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

KRAS Q61H drives acquired resistance to toceranib through sustained RAS–MAPK signaling in canine mast cell tumor cells

Nobuyuki Fujiwara, Ryo Oya, Ryouichi Tsunedomi, Akira Matsuda, Koji Hayakawa, Kosuke Kobayashi, Takashi Ohama

Disease and Therapeutics · 2026

DOI: 10.1016/j.dist.2026.100025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Disease and Therapeutics, 2026. Verfasst von Nobuyuki Fujiwara und 6 weiteren Autor:innen. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Fujiwara, N., Oya, R., Tsunedomi, R., Matsuda, A., Hayakawa, K., Kobayashi, K., & Ohama, T. (2026). KRAS Q61H drives acquired resistance to toceranib through sustained RAS–MAPK signaling in canine mast cell tumor cells. Disease and Therapeutics. https://doi.org/10.1016/j.dist.2026.100025

Vancouver

Fujiwara N, Oya R, Tsunedomi R, Matsuda A, Hayakawa K, Kobayashi K, et al. KRAS Q61H drives acquired resistance to toceranib through sustained RAS–MAPK signaling in canine mast cell tumor cells. Disease and Therapeutics. 2026. doi:10.1016/j.dist.2026.100025

BibTeX
@article{Fujiwara2026,
  author = {Fujiwara, Nobuyuki and Oya, Ryo and Tsunedomi, Ryouichi and Matsuda, Akira and Hayakawa, Koji and Kobayashi, Kosuke and Ohama, Takashi},
  title = {KRAS Q61H drives acquired resistance to toceranib through sustained RAS–MAPK signaling in canine mast cell tumor cells},
  journal = {Disease and Therapeutics},
  year = {2026},
  doi = {10.1016/j.dist.2026.100025}
}
Kostenlos starten →